Imiquimod: modes of action

@article{Sauder2003ImiquimodMO,
  title={Imiquimod: modes of action},
  author={D.N. Sauder},
  journal={British Journal of Dermatology},
  year={2003},
  volume={149}
}
  • D. Sauder
  • Published 2003
  • Medicine
  • British Journal of Dermatology
Introduction 3 Imiquimod (Aldara; R-837, S-26308), an imidazoquinoline amine, is an immunomodulating agent that was approved in 1997 by the U.S. Food and Drugs Administration for treating external genital and perianal warts. This and related molecules represent a group of immune response modifiers defined as small molecules that directly activate the innate immune system, resulting in cytokine release and costimulatory molecule expression, followed by T-cell activation. Studies using imiquimod… Expand
Viral and Nonviral Uses of Imiquimod: A Review
Background: Imiquimod is a topical immunomodulator that is indicated for the treatment of external genital and perianal warts. This drug has been recently approved for the treatment of actinicExpand
Viral and Nonviral Uses of Imiquimod: A Review
TLDR
This review examines the role of imiquimod 5% cream in the treatment of skin diseases such as actinic keratoses, basal cell carcinoma, Bowen’s disease, lentigo maligna, and extramammary Paget's disease and demonstrates indirect antiviral and antitumor effects. Expand
Advances in the use of topical imiquimod to treat dermatologic disorders
TLDR
Imiquimod is an immune-response modifying agent, first approved by FDA for the topical treatment of external genital and perianal warts in 1997, and has been used for the treatment of a wide variety of dermatologic conditions in which the immune system is thought to play a role in regression of the disease. Expand
Imiquimod Upregulates the Opioid Growth Factor Receptor to Inhibit Cell Proliferation Independent of Immune Function
TLDR
Using pancreatic and colorectal cancer cells, as well as squamous carcinoma cells of the head and neck in tissue culture, it is shown that the imidazoquinolines upregulate the Opioid Growth Factor receptor (OGFr), which in turn stimulates the interaction of the OGF-OGFr axis. Expand
Apoptotic Effect of Morphine, Imiquimod and Nalmefene on Promastigote, Infected and Uninfected Macrophages with Amastigote of Leishmania Major by Flow Cytometry
TLDR
It is deduced that morphine lacks any lethal effect on L. major after 24 h, whereas in groups treated with Glucantime alone or in combination with Nalmephene and Imiquimod, 84.13%, 88.96% and 86.72% of promastigotes were alive, respectively. Expand
Imiquimod: unexpected killer.
  • M. Leverkus
  • Biology, Medicine
  • The Journal of investigative dermatology
  • 2004
Mechanism of Action and Emerging Role of Immune Response Modifier Therapy in Dermatologic Conditions
  • D. Sauder
  • Medicine
  • Journal of cutaneous medicine and surgery
  • 2004
TLDR
The mechanism of action of IRM and the application of IRMs in several dermatologic diseases are reviewed. Expand
Effect of Imiquimod and derivatives compounds EAPB0203 and EAPB0503 on Leukemia/lymphoma models
TLDR
Results in growth inhibition and apoptosis, selectively in AML cells that harbor the N PM-1 mutation reinforce the idea targeting NPM-1m oncoprotein to eradicate leukemic cells and warrant a broader preclinical then clinical evaluation of this promising drug. Expand
Effect of 3M-003, an imidazoquinoline, on phagocyte candidacidal activity directly and via induction of peripheral blood mononuclear cell cytokines.
TLDR
3M-003 acts directly on macrophages to enhance fungal killing and stimulates PBMC to produce soluble factors that enhance killing by neutrophils, macrophage, and monocytes, and could be a candidate for antifungal immunotherapy. Expand
EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma.
TLDR
Results support a potential therapeutic role for EAPB0203 in ATL and HTLV-I-negative T-cell lymphomas, either as a systemic or topical therapy for skin lesions. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
A review of the applications of imiquimod: a novel immune response modifier
  • T. Syed
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2001
TLDR
As a potent immune response modifier and an agent stimulating cell-mediated immune responses, imiquimod appears to be a promising drug to treat many skin disorders, infections and neoplasms. Expand
Immunomodulatory and pharmacologic properties of imiquimod.
  • D. Sauder
  • Medicine
  • Journal of the American Academy of Dermatology
  • 2000
TLDR
Results from animal studies have indicated a possible use for imiquimod in the prevention and treatment of herpes simplex virus infection and recent studies demonstrated that imiquIMod activates Langerhans' cells and enhances allergic contact hypersensitivity. Expand
Imiquimod applied topically: a novel immune response modifier and new class of drug.
TLDR
Imiquimod is expected to be effective where exogenous IFN-alpha has shown utility and where enhancement of cell-mediated immunity is needed and will likely lead to benefits in several other chronic virus infections and tumors of the skin. Expand
Imiquimod and resiquimod as novel immunomodulators.
TLDR
The imidazoquinolinamines imquimod and resiquimod have demonstrated potency as inducers of IFN-alpha and other cytokines both in vitro and in vivo and may find roles in the therapy of cancers and as vaccine adjuvants. Expand
Imiquimod: a cytokine inducer.
  • M. Dahl
  • Medicine
  • Journal of the American Academy of Dermatology
  • 2002
TLDR
The use of topically applied imiquimod (Aldara, R-837, S-26308) for the treatment of various viral, malignant, and premalignant neoplasms and for the prevention of keloids is addressed and it is suggested that induction of cytokine synthesis by imiquIMod does not depend on irritation. Expand
Imiquimod (Aldara): modifying the immune response.
  • S. Rudy
  • Medicine
  • Dermatology nursing
  • 2002
TLDR
Imiquimod 5% cream represents a new class of topically applied immune response modifiers that are capable of enhancing immune function and shows promise for wide applicability in treating other viral skin infections as well as neoplastic and immune-mediated diseases of the skin. Expand
The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells.
TLDR
It is indicated that imiquimod and R-848 dissociate the functional maturation (cytokine-mediated) and phenotypic maturation of epidermal LC and warrant further exploration for the use of imidazoquinoline-treated LC or other DC subsets for processing and presentation of viral peptides to Th-lymphocytes as a novel vaccine strategy to induce protective antiviral responses. Expand
Topical imiquimod: a review of its use in genital warts.
TLDR
Imiquimod 5% cream is a new therapeutic option for patients with genital warts and produces clearance rates broadly similar to those of other treatment approaches and rates of wart recurrence compare favourably with those reported for established treatments. Expand
Topical immunomodulators--progress towards treating inflammation, infection, and cancer.
TLDR
Topical immunotherapy with immunostimulatory agents shows potential for effective and patient-friendly treatment of inflammatory, infectious, and cancerous skin diseases. Expand
Imiquimod, a topical immune response modifier, induces migration of Langerhans cells.
TLDR
Imiquimod did enhance Langerhans cell migration from skin to draining lymph nodes and was also associated with an enhanced allergic contact hypersensitivity, suggesting that the mechanism of modulation of immune response by imiquIMod is in part due to effects on Langershans cells. Expand
...
1
2
3
...